Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Sanofi SA — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.04, while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Sanofi SA is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | SNY | |
|---|---|---|
52-Week High | $97.99 | $52.34 |
52-Week Low | $92.76 | $41.33 |
Market Cap | — | $104.30B |
Sector | — | Health |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $93.075 with a modest 0.34% daily gain, though technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF maintains consistent dividend distributions, with recent payouts of $0.31-$0.32 per share. Market sentiment is influenced by Treasury yield fluctuations and institutional positioning, with Bank of America increasing its stake by 69.8% in Q2 2026.
The outlook remains cautious as rising Treasury yields and inflation concerns pressure bond ETFs. Institutional accumulation provides support, but technical weakness and macroeconomic headwinds suggest limited near-term upside. Key risks include Fed rate policy uncertainty and oil price volatility affecting inflation expectations.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
